Evidence map›Paper›PMID 42414945›Full record

ArticleBMC infectious diseases2026

Seroprevalence of Rift Valley fever virus and factors associated with exposure in south-central Uganda.

Josephine Nalwadda, Victor Ssempijja, Steven J Reynolds, Gerald Katushabe, Jonah Omooja, Evan A Mihalakakos, Deepashri Rao, Kyle Rosenke, Mary K Grabowski, Ronald M Galiwango and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Josephine NalwaddaLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, Uganda Virus Research Institute, Entebbe, Uganda.
Victor SsempijjaClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Steven J ReynoldsLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, Uganda Virus Research Institute, Entebbe, Uganda.
Gerald KatushabeLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, Uganda Virus Research Institute, Entebbe, Uganda.
Jonah OmoojaLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, Uganda Virus Research Institute, Entebbe, Uganda.
Evan A MihalakakosLaboratory of Virology, Division of Intramural Research, NIAID/NIH, Rocky Mountain Laboratories, Hamilton, MT, USA.
Deepashri RaoLaboratory of Virology, Division of Intramural Research, NIAID/NIH, Rocky Mountain Laboratories, Hamilton, MT, USA.
Kyle RosenkeLaboratory of Virology, Division of Intramural Research, NIAID/NIH, Rocky Mountain Laboratories, Hamilton, MT, USA.
Mary K GrabowskiDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ronald M GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Robert SsekubuguRakai Health Sciences Program, Kalisizo, Uganda.
David MeyaClinical Epidemiology Unit, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Denis K ByarugabaLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, Uganda Virus Research Institute, Entebbe, Uganda.
Heinz FeldmannLaboratory of Virology, Division of Intramural Research, NIAID/NIH, Rocky Mountain Laboratories, Hamilton, MT, USA. feldmannh@niaid.nih.gov.
David W HawmanLaboratory of Viral Zoonoses, Integrated Research Facility, Division of Intramural Research, NIAID/NIH, Frederick, MD, USA. david.hawman@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRift Valley fever (RVF) poses a recurring public health and economic challenge in Uganda's cattle corridor. It is a mosquito-borne zoonotic disease caused by the Rift Valley fever virus (RVFV), with high livestock density, favorable rainfall patterns, and close human-animal interaction facilitating viral transmission and disease outbreaks. Although RVF outbreaks have occurred, data on human exposure in south-central Uganda remain limited.

methodsThis cross-sectional study assessed the seroprevalence and associated factors of RVFV exposure among selected communities in the greater Masaka-Rakai region of south-central Uganda. Archived human sera (n = 1,199) retrospectively collected between June 2018 and October 2020 from the population-based Rakai Community Cohort Study were analyzed using both indirect in-house and commercial ID Screen

resultsRVFV IgG antibodies were detected in 86 of 1,199 (7.8%) individuals. In multivariable analysis, RVFV seropositivity was significantly associated with residence in agrarian communities and older age groups (25-34 and ≥ 35 years), while pig ownership was associated with lower risks of exposure.

conclusionThese findings suggest RVFV human exposure in south-central Uganda and emphasize the need for strengthened surveillance, targeted prevention, and One Health interventions to protect high-risk groups.

Indexed as

Antibodies, ViralRift Valley FeverRift Valley fever virusAdolescentAdultAgedAnimalsChildChild, PreschoolCross-Sectional StudiesFemaleHumansImmunoglobulin GMaleMiddle AgedRetrospective StudiesAntibodies, ViralImmunoglobulin GArbovirusMosquito-borne diseaseRift Valley fever virusSeroprevalenceUgandaZoonotic infection

Identifiers

PMID42414945
PMCPMC13628802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.